Drug Profile
ODN 2009
Alternative Names: Oligodeoxynucleotide 2009Latest Information Update: 14 Dec 2001
Price :
$50
*
At a glance
- Originator Novartis
- Class Antineoplastics; Antisense oligonucleotides
- Mechanism of Action DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 14 Dec 2001 No-Development-Reported for Cancer in Switzerland (Unknown route)
- 18 Aug 1997 New profile
- 18 Aug 1997 Preclinical development for Cancer in Switzerland (Unknown route)